BN83495 in Prostate Cancer

- 18 December 2024 - 1 mins read

The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy

Related Clinical Trials

18 December 2024 1 mins read

Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?

18 December 2024 1 mins read

Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

18 December 2024 1 mins read

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

18 December 2024 1 mins read

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

18 December 2024 1 mins read

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

18 December 2024 1 mins read

BN83495 in Prostate Cancer

BN83495 in Prostate Cancer

Related Clinical Trials

Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?

Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

Dysport® Pediatric Lower Limb Spasticity Follow-on Study

Dysport® Adult Lower Limb Spasticity Follow-on Study

Dysport® Pediatric Lower Limb Spasticity Study

Dysport® Adult Lower Limb Spasticity Study

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

Dysport in the Treatment of Glabellar Lines in Chinese Subjects